2,356 results on '"Oldenburg, J"'
Search Results
2. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
3. Bleeding phenotype according to factor level in 825 children with non-severe hemophilia; data from the PedNet cohort
4. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
5. Patient-reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase 3 (TALAPRO-2) study
6. PB0624 A-SURE: Intra-Patient Comparison of Prophylactic Effectiveness of a Recombinant Factor VIII Fc Fusion Protein Versus Standard Half-Life Factor VIII in Hemophilia A
7. PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A
8. PB1073 Endothelial Cell-Dependent Activated Protein C Formation is Significantly Decreased in Hereditary Protein C Deficiency Regardless of Underlying Gene Variant and Residual Activity in Plasma
9. PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study
10. PB0830 Inspecting Underlying Pathogenesis Mechanisms of Von Willebrand Disease Variants Sited in A Domains of the von Willebrand Factor
11. OC 07.2 Investigating the Dominant Negative Effect of Heterozygous F13B Gene Mutations Detected from Mild FXIII Deficiency Patients
12. PB1075 APC Response Rates in Factor V Leiden Carriers Correlate with Thrombotic Risk Independent from Endothelial Properties: Results from an Endothelial Cell-Based ex vivo Model of the Protein C Pathway
13. PB0151 The Effect of Single and Combined Knockouts of GABARAPs Proteins Family on FVIII Intracellular Localization and Secretion
14. PB1292 Rationale and Design of PathfinderReal: A Prospective, Non- Interventional Study Assessing Joint Health in Adults With Haemophilia A after Switching to Prophylaxis with Turoctocog Alpha Pegol (N8-GP)
15. OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1
16. OC 33.5 Structural Characterization of Coagulation Factor VIII
17. OC 04.2 B-domain Deleted Factor VIII Shows Clear Differences in Intracellular Processing and Cellular Responses when Compared to Full Length Factor VIII
18. PB1255 An Update on Real-World use of rVIII-SingleChain in Patients with Haemophilia A in Germany: Interim Results from a Prospective, Non- Interventional Study
19. OC 04.3 Prospective FVIII Intracellular Trafficking Routes Involving GABARAP
20. PB1296 A Prospective, Non-Interventional Study to Investigate the Effectiveness of rVIII-SingleChain in Patients with Hemophilia A
21. PO10 Nuwiq Dosing and Outcomes in the Management of Women/Girls with Haemophilia A Needing FVIII Treatment for Surgery - An International, Open-Label, Non-Controlled Study (NuDIMENSION)
22. PB0681 German Experience with Simoctocog alfa during Surgery in Female Haemophilia A Carriers
23. OC 33.3 Evaluating the Impact of anti-PEG Antibodies on Activation of PEGylated Therapeutic FVIII Products
24. PB1198 Retrospective Genotypic Data Analysis of Patients with Suspected Hereditary Fibrinogen Deficiency
25. OC 43.4 Effectiveness of Emicizumab Under Real-World Conditions in Patients of All Ages with Hemophilia a with and Without FVIII Inhibitors: Interim Analysis of the Non-Interventional Study EMIIL
26. PB0158 Preanalytical Quenching of FVIII Using FVIII-Inhibitors Improves the Specificity of Functional Emicizumab Testing
27. LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)
28. PB0143 Induced B Cell Tolerance in Hemophilia A Mice is Destroyed by Infections
29. PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand
30. PB1502 Hemostatic Imbalance Associated with Tamoxifen in Estrogen Receptor-Positive Breast Cancer Patients: An Observational Study
31. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
32. Fibrinogen Bonn (p. Arg510Cys) in the Aα-Chain Is Associated with High Risk of Venous Thrombosis
33. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
34. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies
35. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
36. What Are the Long-Term Toxicities to Be Controlled and Treated?
37. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study
38. Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany
39. Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo
40. Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain
41. An improved understanding of native coagulation factor XIII complex structure using cryo-EM
42. Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII
43. Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A
44. In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia
45. HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany
46. Influenza infections destabilize established immune tolerance in HemA mice
47. Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo
48. Patient-reported symptoms to predict intra-articular location of joint bleeds
49. Digital joint discovery tool to support hemophilia patient education
50. Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.